ALFA Finder| Execution period | 10 years from Initial Closing |
|---|
NSE filing, NSE: GAJA. Summary written from the filing by ALFA Finder's alert engine.
Gaja Alternative Asset Management Ltd: key numbers
- Share price
- ₹134.31
- Market cap
- ₹1,894 Cr
- Revenue (annual)
- ₹135.5 Cr
- Net profit (annual)
- ₹79.66 Cr
- Promoter holding
- 54.23%
- FII holding
- 0.63%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Gaja Alternative Asset Management Ltd
All →Gaja Alternative Asset Management Annual General Meeting
Gaja Alternative Asset Management issued a postal ballot notice on 6 November 2026 seeking shareholder approval for ESOP ratification, Section 186 loans and eleven material related-party transactions. Voting runs from 9 November to 8 December 2026.
Gaja Alternative Asset Management Earnings Call Transcript: Key Takeaways
Q2 PAT ₹64.7 Cr (+54% YoY) includes a ₹15 Cr deferred tax write-back; PBT grew only 13%. Fee income (₹61.3 Cr TTM) roughly covers ₹63.4 Cr expenses, and carry is lumpy and realization-driven.
Gaja Alternative Asset Management Other Announcement
Gaja Asset Management filed its quarterly Monitoring Agency Report for Sep 2026 under Reg 32(6). The report confirms IPO proceeds utilisation was in line with the offer document, with no deviations.
Gaja Alternative Asset Management Investor Presentation: Key Takeaways
Q2 FY27 total income ₹65.5 Cr (+26% QoQ); PAT ₹64.7 Cr, boosted by ₹15 Cr tax reversal. H1 PAT ₹91.9 Cr (+48% YoY). Net worth ₹1,106 Cr, debt-free.
Gaja Alternative Asset Management Dividend
Gaja AAM declared a first interim dividend of Rs. 0.50 per share on November 4, 2026. Record date for FY 27 dividend is November 12, 2026.
Gaja Alternative Asset Management Results Update
Gaja AMC reported Q2 FY27 total income of ₹117.3 Cr and H1 PAT of ₹91.9 Cr. Board declared ₹0.50 per share interim dividend.
Other regulatory approval announcements
All →Arihant Capital Markets Regulatory Approval
Arihant Capital Markets received SEBI in-principle approval to sponsor and set up a mutual fund. Final registration remains subject to SEBI's conditions.
Dr. Reddy's Laboratories Regulatory Approval
Dr. Reddy's Laboratories received marketing authorization from Brazil's ANVISA for its generic semaglutide injection. The approval targets Brazil's diabetes market, estimated at approximately USD 244.6 million.
Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received USFDA final approval for its generic Olopatadine Hydrochloride Ophthalmic Solution 0.7% ANDA. The product's US market is estimated at $20 million, per IQVIA.
Emmbi Industries Regulatory Approval
SEBI exempted the Makrand and Rinku Appalwar business trusts from SAST takeover rules for an internal family share transfer. Control and promoter shareholding remain unchanged.
Bliss GVS Pharma Regulatory Approval
Bliss GVS Pharma's UK subsidiary Asterisk Lifesciences received MHRA marketing authorisation for Mesalazine 1g Suppositories. The approval lets the subsidiary market the product in the UK.
John Cockerill India Regulatory Approval
John Cockerill India received Reserve Bank of India approval for acquiring shares of John Cockerill Metals International SA. This allows the company to proceed with the share-swap acquisition.